[2] Yang J, Zhang R, Han B, et al. Atherogenic lipid profile in patients with statin treatment after acute coronary syndrome: a real-world analysis from Chinese cardiovascular association database [J]. Lipids Health Dis...
TITRATION OF LIPID LOWERING THERAPY AFTER LIPOPROTEIN (A) MEASUREMENT IN BLACK VS. WHITE INDIVIDUALS IN THE AHA LP(A) COHORT AHA-LP(A)队列中黑人与白人测量脂蛋白(A)后的降脂治疗滴定 PHYSICIAN PRESCRIBING PATTERNS, PERCEPTIONS AND KNOWLEDGE...
LipidAssociation,NLA)以及美国心血管预防护理学会反映了冠状动脉疾病患者从急性到慢性的连续过程,适 (PreventiveCardiovascularNursesAssociation,PCNA)用于门诊环境中。同时有益于指导我国基层医疗卫生机 联合发布了《2023AHA/ACC/ACCP/ASPC/NLA/PCNA慢构全科医生对冠状动脉疾病的整体性认知,以及制订综 ...
ContextThe joint cardiovascular practice guidelines of the American College of Cardiology (ACC) and the American Heart Association (AHA) have become
Standard operating procedures (SOPs) that promote, describe and exemplify the use of RMs will also improve QC for the metabolomics and lipidomics communities. Conclusions The application of RMs described in this review may significantly improve data quality to support metabolomics and lipidomics ...
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators N Engl J Med, 341 (1999), pp. 70-76 View in ScopusGoogle Scholar 60 B.R. Chaitman, R.M. Hardison, D. Adler, et al. The Bypass Angioplasty...
Data of participants aged ≥20 years from the fifth phase (2012–2015) of the Tehran lipid and glucose study (N = 10,576) were analyzed, using survey analysis. The weighted prevalence of hypertension among those not on anti-hypertensive medications was 42.7 and 12.6%, applying the ACC/AHA ...
Clinical Usefulness of the Framingham Cardiovascular Risk Profile Beyond Its Statistical Performance: The Tehran Lipid and Glucose Study. Am J Epidemiol. 2012;176(3):177–86. PubMed Google Scholar Khalili D, Asgari S, Hadaegh F, Steyerberg EW, Rahimi K, Fahimfar N, et al. A new ...
Lipid-lowering therapies and response noted in Figure 1b. Patient showed complete lack of response to pro-protein subtilisin kexin-9 (PCSK9) inhibitors. Decision-making Given family history of ASCVD and non-response to PCSK9 inhibitor, patient was referred to genetics. Genetic testing revealed ...
Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin. Liver Dis. 33, 301–11 (2013). Article CAS PubMed PubMed Central Google Scholar Lipscombe, L. et al. 2018 Clinical Practice Guidelines Pharmacologic Glycemic Management of Type 2 Diabetes in Adults Diabetes Canada...